Novartis publishes updated 2015 segment financials reflecting new division structure

  • Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release

  • No change in audited 2015 Consolidated Financial Statements for the total Group

Basel, March 31, 2016 – Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers …

/by

Novartis publishes updated 2015 segment financials reflecting new division structure

  • Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release

  • No change in audited 2015 Consolidated Financial Statements for the total Group

Basel, March 31, 2016 – Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers …

/by

New research highlights need for a competitive functioning biologics market to achieve full potential of biosimilars for patients, healthcare professionals and payors

New research published today in a report from the IMS Institute for Healthcare Informatics – Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.

The report, funded by Novartis, will …

/by

EGA becomes Medicines for Europe

Medicines for Europe is the new name of EGA (European Generic and Biosimilar Medicines Association) as of today. Representing the pharmaceutical companies supplying the largest share of medicines across Europe, Medicines for Europe is the voice of the generic, biosimilar and value added medicines industries in Europe and a leading partner providing better health and better access to all European patients.

Read the media release

/by

Sandoz proud to announce first Novartis Access treatments to Kenya

  • Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries

  • First Novartis Access shipment delivered to Kenya where almost 30% of people die from NCDs every year

Holzkirchen, World Child Cancer Day (March 1, 2016): Sandoz is pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular …

/by